Evidence map›Paper›PMID 39168637›Full record

ReviewGenes & development2024

The MYC-MAF-SAGA axis drives oncogenic gene expression in multiple myeloma.

Hongkuan Wang, Hong Wen, Xiaobing Shi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hongkuan WangDepartment of Epigenetics, Van Andel Institute, Grand Rapids, Michigan 49503, USA.
Hong WenDepartment of Epigenetics, Van Andel Institute, Grand Rapids, Michigan 49503, USA.
Xiaobing ShiDepartment of Epigenetics, Van Andel Institute, Grand Rapids, Michigan 49503, USA xiaobing.shi@vai.org.

Funding

Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged LeukemiasR01CA260666 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN, WEN, HONG · 2021 to 2025
$2.5M
Discovery of small molecules targeting the histone acetylation reader ENLR01CA255506 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI WEN, HONG · 2021 to 2024
$1.7M
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7M
NCI NIH HHS R01 CA255506NCI NIH HHS R01 CA260666NCI NIH HHS R01 CA268440
6 · The paper itself

Abstract

The SAGA complex is an evolutionarily conserved histone acetyltransferase complex and transcription coactivator essential for development and disease. Dysregulation of SAGA is implicated in various human diseases, including cancer. In this issue of

Indexed as

Gene Expression Regulation, NeoplasticMultiple MyelomaProto-Oncogene Proteins c-mafProto-Oncogene Proteins c-mycAnimalsHumansTrans-ActivatorsMAF protein, humanProto-Oncogene Proteins c-mafProto-Oncogene Proteins c-mycTrans-ActivatorsADA2BMAFmultiple myelomaMYConcogenic gene expression programsSAGA complexSANT domain

Identifiers

PMID39168637
PMCPMC11444177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.